First-line single-agent cetuximab in patients with advanced colorectal cancer

Annals of Oncology

Volumn 19, Issue 4, 2008, Pages 711-716

  Pessino, A ^a   Artale, S ^b   Sciallero, S ^a   Guglielmi, A ^a   Fornarini, G ^a   Andreotti, I C ^b   Mammoliti, S ^a   Comandini, D ^a   Caprioni, F ^a   Bennicelli, E ^a   Andretta, V ^a   Siena, S ^b   Sobrero, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Biological therapy; Cetuximab; Colorectal cancer

Indexed keywords

ANTI ACNE AGENT; ANTIHISTAMINIC AGENT; CETUXIMAB; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; TETRACYCLINE;

ACNE; ADULT; AGED; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FEVER; HAIR DISEASE; HUMAN; HUMAN TISSUE; HYPERTRICHOSIS; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MALE; NAUSEA; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PYOGENIC GRANULOMA; RASH; SKIN TOXICITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; XEROSIS;

EID: 41549104310     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm516     Document Type: Article

References (31)

1. Petrelli N, Douglas HO Jr, Herrera L et al. The modulation of fluorouracil by leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-1426.
2. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997; 15: 808-815
3. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-4560.
4. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the courge of treatment. J Clin Oncol 2004; 22: 1209-1214.
5. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequenoe in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
6. Figueras J, Valls C, Rafecas A et al. Resection rate and effect of post-operative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88: 980-985.
7. Nordic Gastrointestinal Tumor Adjuvant Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992; 10: 904-911.
8. Ackland SP, Jones M, Tu D et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93: 1236-1243.
9. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 2003; 361: 457-464.
10. Maindrault-Goebel F, Lledo G, Chibaudel B et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (GFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc Am Soc Clin Oncol 2007; 25: 166s (Abstr 4013).
11. Labianca R, Floriani I, Cortesi E et al. Alternating versus continuous FOLFIRI in advanced colorectal cancer: A randomised GISCAD trial. Proc AM Soc Clin Oncol 2006; 24: 147s (Abstr 3505).
12. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with-poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 2007; 370: 143-152.
13. Punt CJ, Koopman M, Douma J et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study. Proc Am Soc Clin Oncol 2007; 25: 166s (Abstr 4012).
14. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
15. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with chemorefractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
16. Lenz H.-J, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921.
17. Jonker J, Karapetis CJ, Moore M et al. Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Proc Am Assoc Cancer Res 2007 (Abstr LB1).
18. Van Cutsem, E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Proc Am Soc Clin Oncol 2007; 25: 164s (Abstr 4000).
19. National Cancer Institute. Intergroup CALGB 80405. Phase III randomized study of cetuximab and/or bevacizumab in combination with either oxaliplatin, fluorouracil, and leucovorin calcium (FOLFOX) OR irinotecan hydrochloride, fluorouracil, and leucovorin calcium (LIRI) in patients with previously untreated metastatic adenocarcinoma of the colon or rectum. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 455161&version=HealthProfessional&protocolsearchid=37933937 (27 December 2006, date last accessed).
20. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Proc Am Soc Clin Oncol 2007; 25: 172s (Abstr 4035).
21. Cunningham D, Humblet Y, Siena S et al. Cetuximab (C225) alone or in combinition with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 252s (Abstr 1012).
22. Sastre J, Aranda E, Gravalos C et al. Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer. Preliminary results of a TTD phase II study. Ann Oncol 2006; 17 (Suppl 9): Ix114 Abstr 324.
23. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in oolorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279-286.
24. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
25. Sartore-Bianchi A, Moroni M, Veronese S et al. Epidermal growth factor receptor gene copy-number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245.
26. Cunningham MP, Thomas H, Fan Z et al. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 2006; 66: 7708-7715.
27. Salazar RT, Rojo J, Jimenez E et al. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody EMD 72000 administered every three weeks. A phase I pharmacokinetic/ pharmacodynamic study to define the optimal biological dose. Proc Am Soc Clin Oncol 2004; 23: 127 (Abstr 2002).
28. Valbohmer D, Zhang W, Gordon M et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536-3544.
29. Zhang W, Gordon M, Schultheis AM et al. Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab. Proc Am Soc Clin Oncol 2006; 24: 18s Abstr 3028.
30. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648.
31. Nagasaka T, Sasamoto H, Notohara K et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22: 4584-4594.